GSK (LSE:GSK): Assessing Valuation After Recent Share Price Gains and Sector Momentum

GSK (LSE:GSK) has delivered share price gains of 9% over the past month and 16% in the past 3 months, reflecting steady ...
GlobalData on MSN

GSK’s Blenrep gains FDA approval for myeloma treatment

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

FDA clears return of GSK’s once-withdrawn multiple myeloma drug

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

US FDA approves GSK's blood cancer treatment

(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one ...
Fierce Pharma

GSK's once-withdrawn Blenrep gets 2nd wind in US with FDA nod to treat certain myeloma patients

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
Fierce Biotech

ESMO: GSK says 'stay tuned' for more ADC data after partner Hansoh posts 49% response rate

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...
BioSpace

GSK’s Blenrep Makes Comeback With FDA Nod for Third-Line Multiple Myeloma

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
pharmaphorum

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...
Fierce Biotech

Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...